FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy.

“This grant is wonderful news for the company as it will allow us to strengthen our drug’s protection in a market representing approximately 50% worldwide in terms of returns and move forward with our regulatory plan with close communication with EMA” said Carlos Lurigados, co-founder and CEO of FreeOx.

Ox-01 is currently in clinical phase III.

More information

Photo: Carlos Lurigados and Dr Ángel Chamorro, recognised expert in stroke, co-founders of FreeOx - © FreeOx Biotech


Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream